“Loss of drug substance” means the loss of biopharmaceutical substances and has taken on a completely new meaning with the introduction of individual CAR-T cell therapies. In case something happens to the cells during shipping and the CAR-T cell therapy is rendered useless, the patient might – in the worst case – pay with his or her life.
The transport of high-quality biopharma substances is a very tricky issue. Why tricky, you might ask? It is tricky because “drug substance loss“ is a daily occurrence. To date, businesses have accepted a certain degree of loss, as logistics is not part of their core business. But this is about to change.
It is a well-known fact that the logistics process for liquids in the biopharma industry poses a bottleneck. Before the substances, which are generally of very high quality, reach the Fill & Finish Process they usually have to travel a long way; it is not uncommon that they travel halfway around the globe. For instance not every substance that is produced in Switzerland is filled and packaged there.
As is the case with a number of developments, a spontaneous idea and the will to shake things up led to something big. Two young entrepreneurs from Tyrol, Austria, took on the challenge to “hack” the biopharma logistics process, or, in other words, to reinvent if not revolutionize it.
It all starts with a grain of sand that by chance found its way into the oyster. The grain of sand is an annoyance; it poses a problem. The oyster feels disturbed so it deals with the intruder. But how does the oyster go about it – how does the oyster save its problem?